This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (14)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Alert me on articles by topic

Joseph Jankovic, MD

Arch Neurol. 1999;56:785-790.

Few neurological disorders have been more successful in introducing novel therapies than Parkinson disease (PD). However, despite enormous progress, many challenges remain. Although levodopa is still the most effective drug in the symptomatic treatment of PD, adverse effects, particularly motor fluctuations and dyskinesias, limit its usefulness.¹ Furthermore, there is a growing concern about the escalating cost of PD treatment: the cost-benefit aspect of the novel approaches must be balanced against the advantages of long-term experience with established treatments.

From the Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Tex.

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 1999;56(7):893-894.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Neuroprotection in Parkinson Disease
Simpkins and Jankovic
Arch Intern Med 2003;163:1650-1654.
ABSTRACT | FULL TEXT  

Neuropsychiatric Aspects of Parkinson's Disease
Marsh
Psychosomatics 2000;41:15-23.
ABSTRACT | FULL TEXT